Redeye updates its estimates and fair value range following Ngenic’s Q4 report last week. The report was largely in line, although slightly better than we expected. We think 2025 should be a comeback year for Ngenic, given that its balance sheet has strengthened following the rights issue, and the company can now refocus on its core business, which holds a strong value proposition and is seeing positive demand.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/